Showing 1 - 10 of 22
Objective: There are multiple reasons for missing data in observational studies; excluding patients with missing data can lead to significant bias. In this study, we evaluated several methods for assigning missing values to health service utilisation. Design and setting: Cancer of the Prostate...
Persistent link: https://www.econbiz.de/10005243146
Evidence produced by multinational trial-based cost-effectiveness studies is often used to inform decisions concerning the adoption of new healthcare technologies. A key issue relating to the use of this type of evidence is the extent to which trial-wide economic results are applicable to every...
Persistent link: https://www.econbiz.de/10008725811
Sample size and power for cost-effectiveness analysis depend on assumptions about the difference in cost and effect, the standard deviations of cost and effect, the correlation of the difference in cost and effect, the α and β errors and maximum willingness to pay (W). The first seven of these...
Persistent link: https://www.econbiz.de/10010614324
The UK National Institute for Health and Clinical Excellence (NICE) has used its Single Technology Appraisal (STA) programme to assess several drugs for cancer. Typically, the evidence submitted by the manufacturer comes from one short-term randomized controlled trial (RCT) demonstrating...
Persistent link: https://www.econbiz.de/10010614357
Methods for determining sample size requirements for cost-effectiveness studies are reviewed and illustrated. Traditional methods based on tests of hypothesis and power arguments are given for the incremental cost-effectiveness ratio and incremental net benefit (INB). In addition, a full...
Persistent link: https://www.econbiz.de/10010614384
Basic sample size and power formulae for cost-effectiveness analysis have been established in the literature. These formulae are reviewed and the similarities and differences between sample size and power for cost-effectiveness analysis and for the analysis of other continuous variables such as...
Persistent link: https://www.econbiz.de/10010614390
Persistent link: https://www.econbiz.de/10005449108
Various methods have been proposed to address uncertainty in economic evaluations of healthcare programmes. One approach suggested in the literature is to estimate separate confidence intervals for the incremental costs and effects of a new health programme in comparison with an existing...
Persistent link: https://www.econbiz.de/10005449113
Persistent link: https://www.econbiz.de/10005404869
essence of the debate between the two branches of statistics centres on differences in the use of prior information and the … this paper is to discuss the application of frequentist and Bayesian statistics in the pharmacoeconomic assessment of …
Persistent link: https://www.econbiz.de/10005404905